zalutumumab

05/01/2014 - "(111)In-labeled zalutumumab, a human monoclonal human EGFr-targeting antibody, was administered at a nonsaturating dose to 3 mice with xenografted A431 tumors exhibiting high EGFr expression. "
09/15/2011 - "Finally, tumor growth of mutant KRAS-expressing A431 tumor cells, which were resistant to EGFR signaling inhibition, was completely prevented by early treatment with zalutumumab and mAb 018, whereas ADCC-crippled N297Q-mutated variants of both mAbs did not show any inhibitory effects. "
09/15/2011 - "Interestingly, however, both zalutumumab and mAb 018 prevented tumor formation upon early treatment in this model. "
01/01/2021 - "Zalutumumab and buparlisib + paclitaxel had better efficiency, and might be a better selection for patients with programmed death-ligand 1-low/negative tumors than other treatments."
01/01/2010 - "In the low-dose model, zalutumumab and panitumumab similarly prevented tumor growth. "

06/01/2014 - "Patients received weekly infusions of zalutumumab individually titrated to a grade 2 skin rash. "
04/01/2011 - "Zalutumumab dose titration on the basis of rash is safe. "
04/01/2011 - "Zalutumumab was given weekly by individual dose titration on the basis of skin rash. "
09/01/2018 - "Moderate to severe skin rash after zalutumumab during radiation treatment was associated with improved OS, independent of HPV/p16-status. "
09/01/2018 - "Associations between skin rash, treatment outcome, and single nucleotide polymorphisms in head and neck cancer patients receiving the EGFR-inhibitor zalutumumab: results from the DAHANCA 19 trial."

06/01/2014 - "An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck."
10/01/2007 - "Phase I/II clinical and pharmacokinetic study evaluating a fully human monoclonal antibody against EGFr (HuMax-EGFr) in patients with advanced squamous cell carcinoma of the head and neck."
04/01/2011 - "Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial."
04/01/2011 - "Although zalutumumab did not increase overall survival, progression-free survival was extended in patients with recurrent squamous-cell carcinoma of the head and neck who had failed platinum-based chemotherapy. "
04/01/2011 - "In our open-label, parallel-group, phase 3, randomised trial, we randomly allocated patients with squamous-cell carcinoma of the head and neck who were regarded as incurable with standard therapy, a WHO performance status of 0-2, and progressive disease within 6 months of platinum-based therapy in a 2:1 ratio to receive zalutumumab plus best supportive care (zalutumumab group) or best supportive care with optional methotrexate (control group) at medical centres in Europe, Brazil, and Canada. "

01/01/2012 - "Current data from Phase I and II trials identify zalutumumab as a promising drug for the treatment of locally advanced head and neck cancer and recent data from a Phase III randomized trial showed encouraging survival results compared with best supportive care. "
01/01/2012 - "The mechanism of action and data on efficacy and safety of zalutumumab in head and neck cancer. "
01/01/2012 - "Zalutumumab in head and neck cancer."
09/01/2018 - "Associations between skin rash, treatment outcome, and single nucleotide polymorphisms in head and neck cancer patients receiving the EGFR-inhibitor zalutumumab: results from the DAHANCA 19 trial."
01/01/2012 - "Zalutumumab has demonstrated acceptable toxicity in head and neck cancer patients, with rash being the most common adverse event. "

05/01/2009 - "Zalutumumab is under clinical development, mainly for squamous cell cancer of head and neck and there are also ongoing trials in NSCLC and colorectal cancer."